OPKO Health, Inc. (OPK)
NASDAQ: OPK · Real-Time Price · USD
1.190
-0.090 (-7.03%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.

The company’s Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services.

Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.

This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia.

In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others.

The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.

OPKO Health, Inc.
OPKO Health logo
CountryUnited States
Founded2007
IPO DateNov 2, 1995
IndustryDiagnostics & Research
SectorHealthcare
Employees2,997
CEOPhillip Frost

Contact Details

Address:
4400 Biscayne Boulevard
Miami, Florida 33137
United States
Phone305 575 4100
Websiteopko.com

Stock Details

Ticker SymbolOPK
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000944809
CUSIP Number68375N103
ISIN NumberUS68375N1037
Employer ID75-2402409
SIC Code2834

Key Executives

NamePosition
Dr. Phillip Frost M.D., Ph.D.Chairman and Chief Executive Officer
Dr. Jane H. Hsiao M.B.A., Ph.D.Vice Chairman and Chief Technical Officer
Dr. Elias Adam Zerhouni M.D.President and Vice Chairman
Adam E. LogalSenior Vice President and Chief Financial Officer
Steven D. Rubin Esq., J.D.Executive Vice President of Administration and Director
Dr. Gary J. Nabel M.D., Ph.D.Chief Information Officer and Director
Dr. Arie Gutman Ph.D.President of API
Dr. Akhtar Ashfaq FACP, FASN, M.D.Senior Vice President of Clinical Research and Development and Medical Affairs - Opko Renal
Giovanni Abbadessa M.D., Ph.D.Chief Medical Officer of ModeX
Dr. John R. Mascola M.D.Chief Scientific Officer of ModeX

Latest SEC Filings

DateTypeTitle
Jul 31, 202510-QQuarterly Report
Jul 31, 20258-KCurrent Report
Jul 9, 2025SCHEDULE 13G/AFiling
May 29, 20258-KCurrent Report
May 1, 202510-QQuarterly Report
Apr 30, 20258-KCurrent Report
Apr 23, 20258-KCurrent Report
Apr 3, 2025SCHEDULE 13D/AFiling
Apr 3, 2025SCHEDULE 13D/AFiling
Apr 1, 20258-KCurrent Report